Targeted inhibition of ABL1 and several related kinases by imatinib (Gleevec, Novartis) has become the successful front-line therapy for chronic myeloid leukemia (CML) and several solid tumors 1. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.